Four-year Data from ILLUMENATE Pivotal Trial Reaffirms Safety Profile of Philips Stellarex Low-dose Drug-Coated Balloon

Amsterdam, the Netherlands and Leipzig, Germany, Jan. 28 (Korea Bizwire) – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the four-year results from the randomized controlled ILLUMENATE Pivotal trial in the U.S. With an excellent follow-up compliance rate of over 95% in a highly complex disease patient cohort, the data show [...]